KKR has acquired a majority stake in HealthCare Royalty Partners, pushing the investment firm further into the healthcare ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

Investment firm KKR (NYSE:KKR) announced on Wednesday the acquisition of a majority stake in biopharma royalty acquisition company, HealthCare Royalty Partners. The acquisition marks KKR's expansion ...

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

Contacts HealthCare Royalty Partners Carlos Almodovar, 203-487-8311 [email protected] ...

HealthCare Royalty Partners (HCRP) is a global healthcare investment firm focused on investing primarily in commercial stage healthcare product assets. HCRP manages over $3 billion and is ...

HealthCare Royalty Partners has closed its latest health-care private equity fund, HealthCare Royalty Partners IV, with a total of $1.8 billion for the fund and affiliated entities, a news release ...

HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA ® in the United States in exchange for future hyperphosphatemia royalty payments from Ardelyx Japanese collaboration ...

TORONTO, Jan. 7, 2019 /CNW Telbec/ - , a multi-strategy alternative asset manager, today announced the launch of Sagard Healthcare Royalty Partners ("SHRP"), under the leadership of David MacNaughtan.

Today, Sagard invests across 4 asset classes; equity, private credit (Sagard Credit Partners), royalties (Sagard Healthcare Royalty Partners), and venture capital (Portag3 Ventures and Diagram).

Contacts HealthCare Royalty Partners Carlos Almodovar, 203-487-8311 [email protected] ...